ClinicalTrials.gg
RecruitingNCT07433660THRIVEUpdated Mar 2, 2026

WellSpan-THRIVE Cancer QOL Study

An observational study in Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors) and Cancer (With or Without Metastasis), sponsored by WellSpan Health. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by WellSpan Health · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.

This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.

Read the detailed description

Cancer is a leading cause of morbidity and mortality worldwide. With more than 10 million deaths in 2020, it is imposing a significant burden on individuals, families, and healthcare systems. Cancer treatment often involves a combination of therapies, such as surgery, chemotherapy, and radiation therapy, which can lead to a range of physical and psychological side effects. Side effects such as fatigue, pain, and neuropathy can greatly affect a cancer patient's quality of life, impacting their ability to function, their emotional health, and their social relationships. Research into cancer-related quality of life (QOL) has become increasingly important, as it helps us understand how cancer impacts every part of a patient's life, not just survival. Involving patients in their own care is a powerful way to boost engagement and gain deeper insight into the factors that influence quality of life during the cancer journey.

Many studies have looked at what affects quality of life (QOL) in cancer patients. Factors such as age, stage of disease, type of cancer, education, income, and treatment side effects all play a role. For example, older age, advanced cancer, and certain types like lung or pancreatic cancer can lower QOL, while treatment side effects such as fatigue, pain, and neuropathy can make it harder for patients to do daily activities and enjoy life. Research has made important progress in understanding how physical, emotional, and social issues impact well-being, but challenges remain in fully capturing all the factors that influence QOL for people living with cancer.

The goal is to bridge this gap by developing and implementing a patient-centered quality of life (QOL) survey tailored specifically for cancer patients and aims to capture a more accurate and comprehensive picture of the factors that affect their quality of life.

02

Conditions studied

  • Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
  • Cancer (Solid Tumors)
  • Cancer (With or Without Metastasis)
  • Cancer - Ovarian
  • Cancer Abdomen
  • Cancer (Advanced Stage)

Keywords

  • Cancer
  • Quality of Life
  • QOL
  • Registry
  • Patient
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

WellSpan Health is the lead sponsor of 30 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Newly diagnosed with a- primary cancer within the past six months from WellSpan cancer centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and above
  • Primary cancer diagnosis (newly diagnosed within the past 6 months)
  • Able to sign .

Exclusion criteria

Exclusion Criteria:

  • Patients with age\<18 years,
  • Patients with primary non-melanoma skin, neurological (Brain or ), and primary hematological malignancies.
  • Patients with severe cognitive impairment, unable to sign or unable to complete quality of life questionnaire.
  • Patients with of \<90 days, in the opinion of treating investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Patients Diagnosed with primary cancer in past 6 months

    Patients Diagnosed with primary cancer in past 6 months will be divided into Race, ethnicity and gender and will be looked for differences in quality of life based on these subsets.

06

What researchers measure

Primary outcomes

  1. Quality of Life Differences based on Race or Ethnicity or Gender

    Quality of Life Differences based on Race or Ethnicity or Gender based on Quality-of-life questionnaire. We will look for changes in each question on Quality-of-life from baseline to 6-12-18-24 months.

    Time frame: Baseline, 6-12-18-24 months

07

Study locations

5 of 5 sites recruiting
  • WellSpan Medical Oncology & Hematology
    Chambersburg, Pennsylvania 17201, United States
    Recruiting
  • WellSpan Ephrata Cancer Center
    Ephrata, Pennsylvania 17522, United States
    Recruiting
  • WellSpan Adams Cancer Center
    Gettysburg, Pennsylvania 17325, United States
    Recruiting
  • WellSpan Sechler Family Cancer Center
    Lebanon, Pennsylvania 17042, United States
    Recruiting
  • WellSpan York Cancer Center
    York, Pennsylvania 17403, United States
    Recruiting
08

References and documents

Publications

  • Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570. PubMed 8445433 ↗
  • Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001 Apr;28(3):465-70. PubMed 11338755 ↗
  • Yennurajalingam S, Rodrigues LF, Shamieh O, Tricou C, Filbet M, Naing K, Ramaswamy A, Perez-Cruz PE, Bautista MJS, Bunge S, Muckaden MA, Sewram V, Fakrooden S, Noguera-Tejedor A, Rao SS, Liu D, Park M, Williams JL, Lu Z, Cantu H, Hui D, Reddy SK, Bruera E. Perception of Curability Among Advanced Cancer Patients: An International Collaborative Study. Oncologist. 2018 Apr;23(4):501-506. doi: 10.1634/theoncologist.2017-0264. Epub 2017 Nov 20. PubMed 29158371 ↗
  • Grabner M, Molife C, Wang L, Winfree KB, Cui ZL, Cuyun Carter G, Hess LM. Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. JMIR Cancer. 2021 Apr 12;7(2):e23161. doi: 10.2196/23161. PubMed 33843600 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗

Individual participant data

Plan to share: No — We don't have patient and institution permission to share individual participant data (IPD).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2031, 60 months later.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 25, 2026
StartEst.
Feb 2026
Primary completionEst.
Feb 2031
CompletionEst.
Dec 2031
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433660
Lead sponsor
WellSpan Health
Responsible party
Rahul Kashyap (Medical Director Research, WellSpan Health) — Principal investigator
First posted
Feb 25, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Mar 2, 2026

Study contacts

Joan K Moore, MSN, RN, OCN, CCRP
Contact
jmoore@wellspan.org
717-741-8124
Rahul Kashyap, MBBS, MBA, FCCM
Contact
rkashyap@wellspan.org
717-851-4611
Navesh Sharma, DO, PhD, FACRO
principal investigator · WellSpan Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion